Omalizumab (Xolair®) increased the time to first exacerbation in patients with moderate-to-severe asthma compared with placebo

被引：0
|
作者：
O'Brien, JA
Fox, H
Thirlwell, J
机构：
[1] City Pk Med Ctr, Cape Town, South Africa
[2] Novartis Res Ctr, Horsham, W Sussex, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2001年 / 107卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
358
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [41] ASTHMA SEVERITY AND INCREASED RISK OF CARDIOVASCULAR AND CEREBROVASCULAR OUTCOMES IN PATIENTS WITH MODERATE-TO-SEVERE PERSISTENT ASTHMA.
    Omachi, T. A.
    Haselkorn, T.
    Miller, D. P.
    Shah, M.
    Eisner, M. D.
    Chen, H.
    Iribarren, C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (05) : A37 - A37
  • [42] Prediction of clinical response to omalizumab in moderate-to-severe asthma patients using the change in total serum IgE level
    Li, Bohou
    Huang, Minyu
    Huang, Shuyu
    Zeng, Xiaoli
    Yuan, Yafei
    Peng, Xianru
    Zhao, Wenqu
    Ye, Yanmei
    Yu, Changhui
    Liu, Laiyu
    Ou, Chunquan
    Cai, Shaoxi
    Zhao, Haijin
    JOURNAL OF THORACIC DISEASE, 2020, 12 (12) : 7097 - 7105
  • [43] Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: a systematic review and meta-analysis
    Liao, Junyi
    Tang, Jia
    Jiang, Yuanping
    Wang, Youwen
    Ding, Jiali
    He, Yong
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2024, 18
  • [44] Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
    Colombo, Giorgio Lorenzo
    Di Matteo, Sergio
    Martinotti, Chiara
    Oselin, Martina
    Valentino, Maria Chiara
    Bruno, Giacomo Matteo
    Pitotti, Claudia
    Menzella, Francesco
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [45] Antitussive Use in Patients with Inadequately Controlled Moderate-to-Severe Asthma: A Post Hoc Analysis of the Omalizumab EXTRA Trial
    Rutland, Cedric J.
    Iweala, Onyinye I.
    Anders, Kyle
    Ko, Jinnie
    Mital, Parul
    Gupta, Sachin
    Mohan, Arjun
    JOURNAL OF ASTHMA AND ALLERGY, 2023, 16 : 661 - 665
  • [46] Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
    Wechsler, Michael E.
    Ruddy, Marcella K.
    Pavord, Ian D.
    Israel, Elliot
    Rabe, Klaus F.
    Ford, Linda B.
    Maspero, Jorge F.
    Abdulai, Raolat M.
    Hu, Chih-Chi
    Martincova, Renata
    Jessel, Andreas
    Nivens, Michael C.
    Amin, Nikhil
    Weinreich, David M.
    Yancopoulos, George D.
    Goulaouic, Helene
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (18): : 1656 - 1668
  • [47] Omalizumab (Xolair®) first anti-IgE antibody for treatment of poorly controlled severe persistent allergic asthma
    Pierre, Jacques
    PRESSE MEDICALE, 2007, 36 (03): : 444 - 444
  • [48] A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
    Piper, Edward
    Brightling, Christopher
    Niven, Robert
    Oh, Chad
    Faggioni, Raffaella
    Poon, Kwai
    She, Dewei
    Kell, Chris
    May, Richard D.
    Geba, Gregory P.
    Molfino, Nestor A.
    EUROPEAN RESPIRATORY JOURNAL, 2013, 41 (02) : 330 - 338
  • [49] Treating moderate-to-severe allergic asthma with antiIg-IgE monoclonal antibody (omalizumab). An Update
    D'Amato, G.
    Perticone, M.
    Bucchioni, E.
    Salzillo, A.
    D'Amato, M.
    Liccardi, G.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 41 (04) : 135 - 140
  • [50] Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States
    Sullivan, Patrick W.
    Li, Qianyi
    Bilir, S. Pinar
    Dang, Joseph
    Kavati, Abhishek
    Yang, Ming
    Rajput, Yamina
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (01) : 23 - 32
12345